Bluebird Cash Conversion Cycle vs Ev To Free Cash Flow Analysis
BLUE Stock | USD 0.41 0.03 7.89% |
Bluebird Bio financial indicator trend analysis is way more than just evaluating Bluebird bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bluebird bio is a good investment. Please check the relationship between Bluebird Bio Cash Conversion Cycle and its Ev To Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.
Cash Conversion Cycle vs Ev To Free Cash Flow
Cash Conversion Cycle vs Ev To Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bluebird bio Cash Conversion Cycle account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Bluebird Bio's Cash Conversion Cycle and Ev To Free Cash Flow is -0.11. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Bluebird bio, assuming nothing else is changed. The correlation between historical values of Bluebird Bio's Cash Conversion Cycle and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Bluebird bio are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Cash Conversion Cycle i.e., Bluebird Bio's Cash Conversion Cycle and Ev To Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.11 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cash Conversion Cycle
Ev To Free Cash Flow
A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.Most indicators from Bluebird Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bluebird bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.At present, Bluebird Bio's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 386.4 M, whereas Tax Provision is projected to grow to (119.7 K).
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 529.9M | 275.7M | 273.8M | 373.9M | Cost Of Revenue | 38.9M | 10.1M | 33.5M | 36.1M |
Bluebird Bio fundamental ratios Correlations
Click cells to compare fundamentals
Bluebird Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bluebird Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.7B | 1.8B | 593.8M | 554.9M | 619.2M | 1.1B | |
Other Current Liab | 141.6M | 180.1M | 78.5M | 52.0M | 9.0M | 8.6M | |
Total Current Liabilities | 223.6M | 203.6M | 153.0M | 128.2M | 200.1M | 114.3M | |
Total Stockholder Equity | 1.3B | 1.4B | 374.3M | 196.3M | 194.5M | 184.8M | |
Other Liab | 58.0M | 48.0M | 54.6M | 93K | 107.0K | 101.6K | |
Property Plant And Equipment Net | 337.1M | 346.9M | 101.2M | 291.4M | 267.0M | 174.1M | |
Current Deferred Revenue | 18.9M | 11.6M | 2.3M | 1.5M | 1.4M | 1.3M | |
Net Debt | (136.2M) | (124.7M) | (71.6M) | 168.4M | 193.6M | 203.3M | |
Retained Earnings | (2.3B) | (2.9B) | (3.7B) | (4.0B) | (4.3B) | (4.0B) | |
Accounts Payable | 43.0M | 13.8M | 25.9M | 14.9M | 18.5M | 15.1M | |
Cash | 327.2M | 317.7M | 161.2M | 113.0M | 221.8M | 287.0M | |
Non Current Assets Total | 575.3M | 565.7M | 257.3M | 355.4M | 337.5M | 352.4M | |
Non Currrent Assets Other | 79.2M | 72.8M | 53.3M | 52.1M | 54.3M | 35.0M | |
Other Assets | 79.2M | 72.8M | 53.3M | 52.1M | 59.9M | 33.2M | |
Cash And Short Term Investments | 1.2B | 1.3B | 396.6M | 181.7M | 209.0M | 198.6M | |
Common Stock Total Equity | 547K | 554K | 665K | 711K | 817.7K | 431.4K | |
Common Stock Shares Outstanding | 55.2M | 62.2M | 68.9M | 78.6M | 192.8M | 202.4M | |
Short Term Investments | 531.6M | 982.7M | 779.2M | 833.5M | 138.3M | 67.3M | |
Liabilities And Stockholders Equity | 1.7B | 1.8B | 593.8M | 554.9M | 638.1M | 1.1B | |
Non Current Liabilities Total | 218.9M | 222.6M | 66.5M | 230.3M | 224.5M | 161.3M | |
Other Current Assets | 45.7M | 522.2M | 25.6M | 8.6M | 9.9M | 9.4M | |
Other Stockholder Equity | 3.6B | 4.3B | 4.1B | 4.2B | 4.8B | 5.1B | |
Total Liab | 442.4M | 426.2M | 219.5M | 358.6M | 424.6M | 275.6M | |
Property Plant And Equipment Gross | 337.1M | 346.9M | 121.6M | 313.3M | 308.9M | 181.3M | |
Total Current Assets | 1.2B | 1.2B | 336.5M | 199.5M | 281.7M | 267.6M | |
Accumulated Other Comprehensive Income | (1.9M) | (5.5M) | (2.9M) | (4.1M) | (3.7M) | (3.8M) | |
Short Term Debt | 20.2M | 9.7M | 46.3M | 88.2M | 101.5M | 106.6M | |
Common Stock | 554K | 665K | 711K | 830K | 954.5K | 1.0M | |
Property Plant Equipment | 151.2M | 162.8M | 101.2M | 291.4M | 335.1M | 351.8M | |
Net Tangible Assets | 1.3B | 1.3B | 368.6M | 185.8M | 213.7M | 203.0M | |
Net Receivables | 12.8M | 2.4M | 11.4M | 10.8M | 22.2M | 23.3M | |
Retained Earnings Total Equity | (1.5B) | (2.3B) | (2.9B) | (3.7B) | (3.3B) | (3.2B) | |
Capital Surpluse | 3.4B | 3.6B | 4.3B | 4.1B | 4.7B | 2.6B | |
Inventory | (144.3M) | (149.7M) | (108.5M) | (1.4M) | 22.9M | 24.1M | |
Non Current Liabilities Other | 218.9M | 222.6M | 93K | 92K | 105.8K | 100.5K | |
Intangible Assets | 14.3M | 10.0M | 5.6M | 4.9M | 10.4M | 10.8M | |
Long Term Investments | 506.1M | 131.5M | 122.9M | 97.1M | 1.4M | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.